Jupiter Neurosciences

Executive Summary

Jupiter Neurosciences is a clinical-stage biopharmaceutical company developing oral treatments for neuroinflammation, leveraging its patented JOTROL™ micellar delivery platform to enhance resveratrol bioavailability and brain penetration. The company is focused on Alzheimer's disease and rare neurological conditions, with a mission to provide a safe, oral medication option. Currently in Phase 1 clinical development, Jupiter's lead program targets Alzheimer's disease, and its platform has potential for multiple indications. The company's early-stage status and novel delivery technology position it for potential value inflection upon Phase 1 data readout. With a Miami base and a lean operation, Jupiter is well-poised to advance its pipeline, though it remains a high-risk, high-reward investment given the early stage and competitive landscape for Alzheimer's therapeutics.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 Clinical Data Readout for JOTROL in Alzheimer's Disease70% success
• 2026Orphan Drug Designation for Rare Disease Indication50% success
• TBDStrategic Partnership for JOTROL Platform30% success